Skip to content
Screener

Talphera, Inc. TLPH Q2 2026 earnings

Reported August 13, 2026 · After market close

Revenue-
EPS-$0.06Beat by $0.00
EPS estimate-$0.06
“Reaching 75% enrollment in the NEPHRO CRRT study keeps us on track for completion by year-end. Site realignment is complete, with all target clinical sites now activated. We are particularly pleased with the high level of engagement from our principal investigators and study site personnel.”
Vince Angotti

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full
Revenue-—
Operating income-$3.9M-6.3%
Net income-$4.3M-23.6%

Balance sheet

See full
Cash & equivalents$742.0K-89.1%
Total equity$14.4M+117%
Total assets$26.8M+62.3%

Cash flow

See full
Operating cash flow-$3.9M-33.1%

Valuation & ratios

Valuation

as of 06/30/26
See full
Market cap$53.46M+506%
P/S53,456.6×+53,130×

Profitability

See full
Operating margin-1,474,700%-1,527,715pp
Net margin-1,507,600%-1,551,933pp

Returns & leverage

See full
Return on equity-143.4%+42.2pp
Current ratio4.3×+1.4×

Segments

By segment

See full
Single Reportable Segments-—

FAQ

When did Talphera, Inc. report Q2 2026 earnings?
Talphera, Inc. (TLPH) reported Q2 2026 earnings on August 13, 2026 after market close.
What were Talphera, Inc.'s Q2 2026 revenue and EPS?
Talphera, Inc. reported revenue of - and eps of $-0.06 for Q2 2026.
Did Talphera, Inc. beat estimates in Q2 2026?
EPS beat the consensus estimate of $-0.06 by $0.00.
How did Talphera, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 40.0% from $-0.10.
Where can I find Talphera, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001437749-26-027311) and the 10-Q periodic report (0001437749-26-027316) directly on SEC EDGAR. The filing index links above go to sec.gov.